…or severity; angina that awakens the patient from sleep. Patients receiving modified antiplatelet therapy require clinical surveillance for both recurrent ischemia and bleeding. The source…

…50% from baseline. In patients who experience a recurrent atherothrombotic or cardiovascular event within 2 years while receiving maximally tolerated statin based treatment, an LDL…

…ulcer). Patients weighing < 60 kg (maintenance dose of 5 mg recommended instead of 10 mg). Patients receiving medications that increase bleeding risk, including oral…

…should maintain a high index of suspicion for drug induced arrhythmias in patients receiving agents known to alter the electrical properties of the heart (inducing…

…fibrillation, particularly when other therapeutic options cannot be pursued. Patients receiving digoxin may present with symptoms of digitalis toxicity, which manifests across multiple organ systems…

…nonfatal myocardial infarction, nonfatal stroke or coronary revascularization—occurred in 819 patients receiving bempedoic acid (11.7%) and 927 receiving placebo (13.3%). Bempedoic acid…

…C by approximately 50–60%, including in patients receiving background statin therapy and in those unable to tolerate statins, provided that hepatic LDL receptor expression…

…a 50% reduction from baseline. For a patient who experiences a recurrent atherothrombotic event while receiving maximally tolerated statin therapy, an LDL C goal below…

…variable or modest. In phase III studies involving patients with ASCVD or at least one ASCVD risk equivalent who were receiving statins, inclisiran produced a…

…be used to quantify sodium and potassium intake, preferably while the patient is receiving a stable diuretic dose. Other clinical contexts Secondary causes should be…